Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
SWOG Cancer Research Network
Yale University
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Sanofi
Sanofi
Institut Bergonié
GERCOR - Multidisciplinary Oncology Cooperative Group
Sotio Biotech Inc.
AIDS Malignancy Consortium
University of Utah
Washington University School of Medicine
US Oncology Research
Washington University School of Medicine
Academic and Community Cancer Research United
University of Arizona
University of Cincinnati
The University of Texas Health Science Center at San Antonio
Pierre Fabre Medicament
Stanford University
Sumitomo Pharma America, Inc.
Pfizer
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
University of Wisconsin, Madison
Celldex Therapeutics
EMD Serono
Merck KGaA, Darmstadt, Germany
University of Texas Southwestern Medical Center
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Academic and Community Cancer Research United
Fox Chase Cancer Center
SCRI Development Innovations, LLC
Glycotope GmbH
NSABP Foundation Inc
Alliance for Clinical Trials in Oncology
The Methodist Hospital Research Institute
Intergroupe Francophone de Cancerologie Thoracique
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
UNC Lineberger Comprehensive Cancer Center
Louisiana State University Health Sciences Center Shreveport